Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.Pierre Brissot, D. Alberti, Franco Locatelli et al.|Blood|2005Cited by 10
Semi-Quantitative Assessment of Hemosiderin Distribution Accurately Reflects Reductions in Liver Iron Concentration Following Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine in Patients with Transfusion-Dependent Anemia.Yves Deugnier, J. Ford, Bruno Turlin et al.|Blood|2005Cited by 8
Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Is Effective in Reducing Iron Overload in Patients with Advanced Fibrosis and Cirrhosis.Emanuele Angelucci, J. Ford, B. Rabault et al.|Blood|2005Cited by 6